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Prostate cancer (PCa) is the most common cancer and a second cause of cancer death in 
American men 1. Initially tumors are androgen dependent for growth and regress as a 
consequence of the androgen-ablation therapy. However, in spite of the good therapeutic 
response, the majority of these reoccur in a hormone refractory state 2. Since no efficient 
cure has so far been found for the hormone-independent state of the PCa, it has been of 
high interest to identify potential PCa diagnostic biomarkers and therapeutic targets. For 
this purpose the androgen receptor (AR) and the molecular mechanisms of its action are 
being studied in our laboratory. The second focus of this study is androgen target genes. 
One of these, the human six transmembrane protein of prostate 2 (hSTAMP2), is a novel 
androgen regulated gene originally identified by our group 3. Our recent findings suggest 
its possible function in the prostate physiology and pathology. This work involved the 
molecular analysis of its promoter and 5’-flanking sequences. 
 
 
1.1 Prostate gland and androgens  
 
1.1.1  The prostate gland 
The prostate is a walnut-size exocrine gland that surrounds the urethra at the neck of the 
urinary bladder in men (reviewed in 4). Its main function is to store and supply the fluid 
that composes up to 30% of the volume of semen. It develops by the ninth week of 
embryonic life from several sets of tubules envaginating from the primitive posterior 
urethra. The prostate is composed of several lobes that are continuous in an adult. The 
lobes are composed of lined with secretory epithelium alveoli that drain into the prostatic 
urethra through a series of tubules. The secretory parenchyma is held together by smooth 
muscles and connective tissue. 
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1.1.2  Androgens 
Androgens, the male sex steroid hormones, are, in addition to polypeptide growth factors 5, 
required for prostate differentiation and maintenance of its function. Testosterone (TST), of 
which 95% is produced by Leydig cells in testis, is the main androgen circulating in the 
bloodstream of men. In circulation its availability to the tissues is regulated by several 
proteins to which it is bound. These are: sex hormone-binding globulin (SHBG) and to a 
lesser extend albumin and corticosteroid-binding globulin 6. In the prostate, free TST enters 
the cells, where it is converted by the enzyme 5α-reductase to its active form, 5α-
dihydrotestosterone (DHT) (Figure 1). Both TST and DHT can bind to the AR, a member 
of the steroid receptor superfamily; however, DHT’s affinity for the AR is five times higher 
than that of TST. DTH binding induces a change in AR conformation that is more resistant 
to degradation 2. In the absence of androgens, AR resides in the cytoplasm in a complex 
with heat shock proteins (HSPs). Upon ligand binding, it undergoes conformational 
change, dissociates from the HSPs and becomes hyperphosphorylated. The HSP-release 
unmasks dimerization motifs and nuclear localization signal 7. AR is thus ready to enter the 
nucleus, dimerize and bind to androgen response elements (AREs). AREs, located in 
promoters and/or enhancers of androgen regulated genes, are sequences from which AR, in 







Figure 1. General mechanism of androgen mediated gene regulation    
Free testosterone enters the cell through the plasma membrane, and after conversion to DHT by 5α-
reductase binds to the ligand binding domain (LBD) of the AR. AR then dissociates from the 
complex with HSPs, becomes phosphorylated, dimerizes and enters the nucleus where it can bind to 
AREs and, in concert with cofactors, activate/repress gene expression.  (Figure taken from 7)  
 
 
   
1.2 AR and its role in gene transcription 
 
1.2.1  The androgen receptor 
The AR gene is localized on the X chromosome. It has eight exons and is approximately 90 
kilo bases (kb) long. AR is expressed in the majority of tissues and its level depends on the 
tissue type, age and developmental stage 7. Structural analyses have revealed that AR 
contains 4 distinct domains that are more or less conserved among the nuclear receptor 
family members: a highly conserved central deoxyribonucleic acid (DNA)-binding domain 
(DBD), hinge region, carboxy-terminal ligand-binding domain (LBD), and a less conserved 
NH2-terminal domain (NTD) 8,9. Further studies localized two regions responsible for the 
transcriptional activation, 1) a ligand-independent activation domain AF-1 placed in NTD 
and 2) AF-2 situated in the LBD 2. Centrally localized DBD contains nine cysteines, of 
which eight are involved in formation of two zinc-finger domains. In addition to DNA 
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binding, DBD has been implicated in AR nucleo-cytoplasmic shuttling due to the presence 
of a non-classical nuclear export signal 10. Interaction between NTD with LBD has been 
shown to mediate active conformation of the AR and reduce androgen dissociation 11,12. A 
number of phosphorylation sites in the AR have been reported and it has been observed that 
the ligand-induced AR hyperphosphorylation correlates with its activation (reviewed in 
7,13). Recent findings indicate that the phosphorylation pattern is influenced by 
compartmentalization of the AR, where androgen-independent phosphorylation was 
observed for the cytoplasmic AR and androgen-dependent phosphorylation on different 
serine residues was detected on the nuclear AR 14. Phosphorylation specificity and its exact 
function still remain largely unclear. It has been suggested that action of both AR and its 
cofactors are directly modulated by phosphorylation 15,16.  
 
1.2.2  The androgen response elements 
Although heterodimerization has been reported for the AR and the glucocorticoid receptor 
(GR) , it is has been shown that AR binds AREs mainly in a homodimeric manner 7. The 
ARE consensus sequence, GG(A/T)ACAnnnTGTTCT 17, is very similar to that of GR, 
although non-conventional AREs have also been proven important for androgen specificity 
7. Co-localization of AREs with the GR response elements (GREs) suggests that AR, GR as 
well as the rest of nuclear receptors (NRs) interact with same sequences, leaving specificity 
of NR binding still not fully answered 7. For the most highly androgen regulated genes, 
AREs can be found in the proximal promoter as well as in the distant enhancer sequences, 
either upstream or downstream of the first exon 18,19. These multiple AREs are thought to 
cooperate in mediating transcription activation. A looping mechanism (Figure 2) has been 
proposed for the prostate specific antigen (PSA) gene, that involves interaction of AREs 
situated in the proximal promoter and the enhancer placed about 4 kb upstream of the 
transcription start site (TSS) 20.  Recently described ARE containing-enhancer of another 
androgen regulated gene, FK506- binding protein 5 (FKBP5), has been observed as far as 
65 kb downstream, in the fifth intron, and a novel mechanism for indirect communication 
between enhancer and basal transcription machinery has been proposed 18. To point out 
another example, neutral endopeptidase (NEP) gene was analyzed and in addition to 
previously identified ARE in exon 24 and androgen responsive region (ARR) in the NEP 
promoter, ARE1 and ARE2 in 3’ untranslated region (UTR) and intron 17, respectively, 
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have been found 19. These examples illustrate how the placement of AREs can vary greatly 
from one gene to another. 
   
 
Figure 2.   Proposed looping mechanism for the interaction between AREs in the proximal 
promoter and enhancer of the PSA gene 
The contact between AREs located at both sites is bridged by coactivators that together with the 
transcription machinery form a complex with ARs. (Figure taken from 21)  
 
 
1.2.3  The AR dynamics 
Contrary to the widely acknowledged paradigm of stable NR interaction with DNA, a 
recent study of AR dynamics revealed a dramatically more transient character of this 
interaction 22. AR has been shown to recycle between DNA-bound and unbound state with 
a half life of about 10 sec 22. The character of cofactors recruited and the effect on the gene 
expression seems to be dependent on the rate of this recycling, which was shown to be 
slower for the agonist-bound AR, than for the antagonist-bound AR, resulting in gene 
activation 22.  
The dynamics of AR has also been reported to be dependent upon the place in which it is 
bound to DNA. The AR loading and polymerase II (Pol II) recruitment onto the proximal 
promoters and enhancers was monitored by chromatin immunoprecipitation (ChIP) 
analysis in the PSA and kallikrein 2 (KLK2) genes and it was shown that AR residence 
time on the enhancer was more transient than on the promoter 23. Quantification 
experiments undertaken in the same study showed twenty times more AR on the enhancer 
than on the promoter. However, the main Pol II containing complex was assembled on the 
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promoter. Both AREs in the enhancer and the promoter were needed for the maximum 
activity 23. 
 
1.2.4  AR action and its cofactors 
ARE-bound AR is able to recruit the transcription machinery and its N-terminus has been 
shown to interact with transcription factor IIF (TFIIF) and TATA box-binding protein 
(TBP) 24. AR-mediated transcriptional activation or repression depends on the character of 
recruited cofactors, most of which are also utilized by other members of the steroid 
hormone receptors. Coactivators include the p160 family, p300/CBP-associated factor 
(P/CAF), cAMP response element-binding (CREB)-binding protein (CBP) and p300, all of 
which have the intrinsic histone acetyltransferase (HAT) activity. Other AR-associated 
coactivators are: androgen receptor associated coregulator (ARA) 70, ARA55 and ARA54 
25. Still another coactivator, SWI/SNF, possesses adenosine 5'-triphosphate (ATP)-
dependent chromatin remodeling activities, and TRAP/DRIP mediates recruitment of the 
core transcription factors 26. Jumonji domain containing 2C (JMJD2C) and lysine-specific 
histone demethylase 1 (LSD1) are histone demethylating proteins that have been shown to 
associate with AR and cooperatively demethylate lysine 9 on histone 3 and thus aid 
androgen regulated gene activation 27,28. Taken together, so far identified AR coactivators 
seem to contribute to gene transcriptional regulation in many different ways. This variety 
may account for the gene- and context-dependent specificity of AR’s action. 
 
In the presence of an antagonist, AR can recruit corepressors, as it has been shown for the 
bicalutamide-bound AR 29. Corepressor complexes include the nuclear receptor corepressor 
(NCoR) and silencing mediator for retinoic acid receptor and thyroid-hormone receptor 
(SMRT) that in turn recruit histone deacetylase (HDAC) activity containing the corepressor 
complexes Sin3/Rpd3 and nucleosome remodeling and deacetylating (NuRD) complex 30. 
In addition it has been reported that NCoR and SMRT also can be recruited by agonist-
bound AR and thus, in the presence of DHT, the outcome of AR’s action depends on the 
relative levels of coactivators versus corepressors, both competing for AR binding 31. 
Conversely it has been shown that AR antagonists can act as agonists in cells with 
increased AR level and this antagonist-agonist conversion is associated with alterations in 
the recruitment of cofactors to the promoters of AR target genes 32. The fact that AR’s 
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action outcome not only depends on the ligand, but also on the context (specific cofactors 
present) at the transcription site, may further explain complexity and specificity of AR 
action. It is important to mention that in addition to the proteins which cooperate with AR 
at the gene locus, there are other factors that can modulate AR mediated gene activation by 
modulating AR activity, before it enters the nucleus. For instance, caspase 8 has recently 
been shown to repress AR-dependent gene expression by disrupting AR amino- and 
carboxy-terminal interactions and thus preventing nuclear translocation of AR 33. 
In addition to directly affecting transcription, AR has also been shown to indirectly act on 
gene expression in an androgen-independent manner. Some of this evidence comes from 
the studies of the AR’s occupancy of DNA at the PSA locus. In the absence of androgen, 
AR was shown to be absent from any site in the PSA locus in the prostate cancer cells; 
however, ribonucleic acid (RNA) interference mediated AR knockdown further reduced 
already low PSA expression. This suggests that the low androgen-independent PSA 
expression still requires functional AR 34. In another study by the same group, the PSA 
expression in the absence of DHT was shown to be significantly higher for the androgen-
independent cell line, than for the androgen sensitive cell line 35. It was shown that this was 
a result of ligand-independent AR binding to the PSA promoter, even though the level of 
the steady-state AR occupancy was relatively low. This study suggests a link between the 
transcription activating chromatin modifications and sustained AR signaling 35. Studies of 
histone modifications at the androgen target gene loci as well as knock down of HDAC- 
inhibitors further confirmed the importance of histone modification-state in AR-dependent 
gene activation/repression 23,36.  
 
Another mechanism for AR-dependent transcription activation, that is independent on 
DNA binding, so called “triggering” of coactivators have been suggested 37. In this study it 
was observed that the AR could activate transcription through binding to coactivators 
without itself being tethered to DNA. These AR-coactivator interactions were shown to 
involve distinct AR and coactivator regions than in case when AR itself was bound to DNA 
37. Another nonclassical, independent of AR-DNA interaction, actions of androgens has 
been described in Steroli cells where androgen was capable of regulating CREB-mediated 
gene expression via the mitogen-activated protein kinase (MAPK) pathway 38. 
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1.3 AR target genes 
 
High throughput gene expression analysis techniques, like serial analysis of gene 
expression (SAGE), massively parallel signature sequencing (MPSS), and microarray-
based techniques,  have allowed for identification of potential androgen regulated genes in 
cells of prostate origin 25. As mentioned before, the best understood action of AR is thought 
to involve DNA binding and requires the presence of the AREs in the gene locus. Prostate 
specific antigen (PSA) is probably the best characterized androgen regulated gene. It is 
situated in the kallikrein locus on the chromosome 19q and codes for secreted glycoprotein 
that belongs to the kallikrein family of serine proteases 39. Requirement of the AR for PSA 
expression has been demonstrated in the androgen-negative and PSA-negative prostate 
cancer cells, PC-3, in which transfection of the AR and androgen treatment induced PSA 
expression in a AR dependent manner 40. Transcriptional regulation of PSA involves 
synergetic interaction between multiple AREs, of which two are situated in the proximal 
promoter (AREI and AREII) and one cluster of AREs is placed in upstream enhancer 
(AREIII) about four kilobases away (Figure 3) 21. Acetylation events and chromatin 
remodeling have been reported around all three AREs. Mutational analysis showed 99% 
reduction in PSA promoter activity, when the AREIII was mutated, with 80% and 50% for 
AREI and AREII respectively 29,41,42. Based on ChIP analysis and insulator studies of the 
entire region spanning from the enhancer to the promoter, a combined model for PSA 
enhancer-promoter interaction has been proposed 20. It involves both physical enhancer-
promoter contact mediated by DNA looping and mediator complex, and tracking of the 
polymerase through the whole 4kb from the enhancer to the promoter. This Pol II tracking 
is dependent on Pol II C-terminal domain (CTD) phosphorylation 20. Other non-consensus 
and weak AREs, present in the PSA locus, may contribute to its transcriptional activation, 
together with the putative cAMP response element (CRE) site found in the enhancer 43. In 
addition, some other factors were indicated to enhance PSA expression, including two 
other steroid receptors (glucocorticoid receptor and progesterone receptor) 44-46, as well as 




Figure 3.   The PSA 5’ regulatory region 
The regulatory region consists of the promoter with two AREs, SP-1 site and TATA box and the 
enhancer with the multiple AREs and the single CRE. (Figure taken from 21)  
 
 
To name another example of AR-target genes, NKX3.1, is a human homeobox gene, that 
maps to 8p21 region, of which loss of heterozygosity has been reported to be associated 
with tissue differentiation and loss of androgen-responsiveness 50. NKX3.1 has been found 
to be specifically expressed in the prostate epithelium and its expression in the LNCaP cell 
line has been shown to be upregulated in a time- and androgen concentration- dependent 
manner 50.  Prescott and coworkers observed NKX3.1 gene regulation by androgens at the 
transcriptional level, with no need of de novo protein synthesis 51. Other studies showed its 
high expression in an androgen-independent PCa xenograft model in the absence of 
androgens, suggesting NKX3.1 deregulation in advanced PCa 52. Reported nuclear 
localization of the NKX3.1 protein coincides with its proposed function as homeobox TF 
52. Still another androgen-regulated gene, Kallikrein 4 (KLK4), has been identified and 
cloned as the fourth member if the kallikrein protease family 53,54. Different splice-variants 
of the KLK4 mRNA and predominantly nuclear localization of the KLK4 truncated 
variants have been reported 55.  KLK4 has also been shown to be regulated by multiple 
hormones in the PCa cells and deregulated in the androgen-independent PCa 55. 
Additionally KLK4 protein has been reported to be highly upregulated in malignant versus 
normal prostate 56. Its overexpression has been shown to induce proliferation of PCa cell 
lines and knockdown of endogenous KLK4 in human lymph node prostate cancer (LNCaP) 
cells inhibited cell growth, suggesting possible role of KLK4 as a poliferative factor in the 
PCa development 56.  
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1.4 Prostate cancer and AR 
 
1.4.1  Prostate cancer 
Androgen-dependent epithelial and stromal growth and differentiation is important for both 
developing prostate and prostatic carcinoma. In this section the events leading to PCa will 
be reviewed, focusing on the AR and its action. According to the statistical analysis in 
United States in 2007, prostate cancer, together with colorectal cancer, is a third cause of 
cancer deaths in men at the age of 40 and above and it accounts for the 29% new cancer 
cases and 31% cancer deaths among men 1. This makes it the most common non skin 
cancer and a third cause of cancer death in men. 
 
After puberty age, the prostate size is regulated by androgens that can stimulate cell 
proliferation and inhibit apoptosis. Most PCas arise from the peripheral zone of the 
prostate. Prostatic intraepithelial neoplasia (PIN) is the first morphologically detectable 
stage of the PCa and can occur as early as in men’s twenties. Further the disease progresses 
slowly, until cancer development around the age of 60 57.  Around one third of local 
prostate tumors can become locally invasive and metastatic, spreading to other tissues; 
bone, liver and lung 57. Initially tumors are androgen dependent for growth and regress as a 
consequence of the androgen-ablation therapy treatment. However the majority of these 
reoccur in a hormone refractory state 2. This reoccurrence characteristic for PCa is believed 
to be the consequence of the clonal selection and epigenetic/adaptive mechanisms. After 
androgen depletion of the multifocal tumors and PIN, the preexisting androgen-
independent cells (~1 in 105 -106) can expand leading to formation of an androgen-
independent tumor. Alternatively, same ratio can reflect the frequency of the mutations 
responsible for “advantageous” genetic or epigenetic events, such as mutations in the AR 
gene that render it responsive to other hormones, changes in signaling pathways that affect 
AR activity,  changes in the level of AR cofactors, etc. (see below) 58. 
 
1.4.2  AR’s role in the prostate cancer development 
Because no effective therapy has yet been found for the reoccurrence of PCa, the main 
focus has been directed on studying the mechanisms that cause progression of PCa from 
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the androgen naive to the hormone refractory state. It has been observed that the androgen-
responsive genes, initially downregulated upon androgen-ablation therapy, become restored 
in the androgen independent tumors 59. This raises a question whether the AR can act in a 
ligand-independent manner, and if so, what are the mechanisms behind it. A number of 
such mechanisms have been proposed, pointing out the AR as a promising potential 
therapeutic target. First, overexpression of the steroid hormone coactivators and of the AR 
itself has been suggested 58. AR gene amplification (leading to both mRNA and the protein 
level increases), as well as its increased stability, activity and nuclear localization has been 
observed in recurrent tumors 58. Moreover, a point mutation in AR LBD has been proposed 
as one of the events that can make the AR sensitive to very low concentration of androgens, 
as well as responsive to other non-androgenic ligands 58. Activation of such hypersensitive 
AR can thus occur in the prostate, where some extracellular androgen is still present even 
after androgen castration. Additionally, the prostate cells have the potential ability to 
provide intracellular source of androgens by  de novo synthesis from cholesterol 58. Both 
hypersensivity of AR to low testosterone level as well as AR ligand-independent activation 
have been proposed to be caused by growth factors 60. Phosphoinositide-3 kinase 
(PI3K)/Akt, or Ras/MAPK signaling pathways, stimulated by auto- and paracrine growth 
factors can cause activation of AR, or its partners, by phosphorylation 13. Thus both 
overexpression of the growth factors and mutations of the components of these signaling 
cascades can lead to elevated activation of AR in the absence of the ligand 13. Finally, there 
is a range of other events that are common for cancer development in general. Some of 
these are loss of tumor suppressor genes, upregulation of oncogenes and overexpression of 
antiapoptotic genes, such as Bcl-2 and Bcl-xL, leading to upregulation of survival 
pathways 61,58. 
 
1.4.3  Investigation of AR target genes  
It has been of high interest to identify potential PCa diagnostic biomarkers or therapeutic 
targets. Appreciating AR’s role in development and progression of PCa, extended studies 
of AR target genes has been conducted and a number of genes have thus been proposed as 
promising therapeutic targets. The previously mentioned homeobox NKX3.1 gene is one of 
these. Its loss by deletion of the chromosome 8p region is associated with hormone-
refractory and malignant stage of PCa, which suggests its possible function as a tumor 
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suppressor gene 50. PSA, described in the previous section, has been widely used as an 
indicator of PCa 62. There is a relatively high rate of false-positive results of  PSA 
screening, because elevated level of PSA may also indicate prostatitis or benign prostatic 
hyperplasia (reviewed in 63). In spite of that some believe that PSA screening tests, leading 
to early diagnosis and treatment, is one of the factors that contribute to declining mortality 
rate of the patients diagnosed with early stages of PCa (reviewed in 64). Researchers have 
thus been focused on detecting novel genes, differentially expressed in healthy versus 
cancerous prostate, and studying their expression regulation including the role of the AR 
and other factors as well as epigenetic mechanisms. As far as epigenetics is concerned, 
locus specific chromatin alterations of the PSA and KLK2 genes have been shown to 
contribute to elevated gene expression both in presence and absence of DHT in the 
androgen-independent PCa cells 35. The microarray technology has made the wide scale 
gene expression analysis possible.  
It is important to mention the model systems that have been used to both identify and study 
newly discovered androgen regulated genes. The LNCaP cell line is the main cell-based 
system used for large-scale gene expression studies and one of the few that retains some of 
the PCa’s features. It is epithelial in origin, expresses AR and AR-regulated genes and is 
androgen sensitive for growth and survival in culture and xenografts 25. It is also essential 
to mention the importance of androgen-independent AR-negative PCa cell lines used in 
PCa studies, with DU 145 and PC-3 being the most widely used lines 65,66. One has to keep 
in mind that each of these cell lines, although all representing relapsed androgen 
independent PCa, arose independently and thus has its own unique characteristics 66. 
Finally, rat prostate 25, and transgenic mice 67,68 have been used to study the PCa in more 
physiological context. However the genetically-engineered mouse models do not 
simultaneously reflect all the changes leading to PCa development in humans. Fundamental 
anatomic differences between human and murine prostate is another caveat of these models 







1.5 STAMP/STEAP family members 
 
1.5.1  STAMP/STEAP family 
In the search for potential targets for prostate cancer diagnostics and treatment, the six-
transmembrane protein of the prostate (STAMP/STEAP (six-transmembrane (6TM) 
epithelial antigen of the prostate)) family has been identified 3,69-75. To date, the identified 
family members include: STEAP, STAMP1(STEAP2), STAMP2(STEAP4)/TIARP (tumor 
necrosis factor α-induced adipose-related protein) (mouse homologue) and 
STAMP3(STEAP3) also called TSAP6 (tumor suppressor-activated pathway-6) and its rat 




Figure 4.   Alignment of the STEAP family members 
Clustal and GenDoc alignment of the STAMP/STEAP family members (hSTAMP2, TIARP, 
hSTAMP1, hTSAP6, pHyde and hSTEAP) is shown. The black shaded residues indicate 
completely conserved residues. Rresidues conserved in 5 or 4 sequences are shaded dark and light 
gray respectively. (Figure taken from 3)  
 
1.5.2  STEAP 
STEAP was originally identified as highly expressed in human prostate tissue70. Also 
known as prostate-specific cell-surface antigen, it was shown to be located at the cell-cell 
junction in the secretory prostatic epithelium. As well as being upregulated in the prostate, 
it has also been shown to be highly expressed in bladder, colon, ovarian and Ewing 
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carcinoma cancer cell lines 70. The mouse homolog, mSTAMP, which has 80% sequence 
homology to STEAP, was cloned from cDNA extracted from a prostate tumor cell line of 
the transgenic adenocarcinoma mouse prostate (TRAMP) mouse71. Mouse STEAP mRNA 
was shown to be largely prostate specific and strongly detected in primary tumor and 
metastasis of the TRAMP mice 71. STEAP, unlike other family members, lacks part of the 
N-terminal domain (Figure 4). 
 
1.5.3  STAMP1/STEAP2 
The six transmembrane protein of prostate 1 (STAMP1) 69, also known as STEAP2 72 , has 
been shown to be up to ten fold higher expressed in normal prostate (epithelial cells) 
compared to other tissues at mRNA level 72. It is also strongly upreguated in prostate 
tumors, both primary and hormone-refractory, with higher expression observed in the latter 
ones. STAMP1 is exclusively expressed in the androgen dependent, AR-positive LNCaP 
cells, with almost undetectable levels in the AR-negative DU145 and PC-3 cell lines 69. Its 
colocalisation to plasma membrane, trans-Golgi network, vesicular tubular structures, as 
well as colocalisation with the early endosome antigen 1 (EEA1) suggests that STAMP1 
may play role in the secretory and endocytic pathways 69,72. 
 
1.5.4  STAMP2/STEAP4 
The six transmembrane protein of prostate 2 (STAMP2) 3 also known as STEAP4 or tumor 
necrosis factor-alpha-induced adipose-related protein (TIARP) 73, is expressed (both at 
mRNA and protein level) at the plasma membrane upon adipocyte differentiation, in 
response to tumor necrosis factor-alpha (TNF-α) 73.  TIARP can be stimulated by 
interleukin (IL)-6, another adipocytokine implicated in pathogenesis of insulin-resistance 
76. Thus in addition to a proposed role in adipocyte development, STAMP2 is thought to 
regulate homeostasis by modulating the interplay between the inflammatory and metabolic 




1.5.5  STAMP3/STEAP3/TSAP6 
The rat homologue of STAMP3 /STEAP3/TSAP6 pHyde, was originally cloned from the 
Dunning rat PCa cells 74. pHyde has been shown to inhibit growth of the DU145 and 
LNCaP cells in vitro and contribute to reduction of the DU145-mouse tumors in vivo, 
possibly through stimulation of p53 and induction of apoptosis 74.  Its ectopic expression 
has been shown to induce apoptosis in DU145 through a caspase-3 dependent pathway 78. 
STAMP3/TSAP6 is a p53 inducible protein (with p53-response elements found in its 
promoter) that regulates apoptosis and cell cycle by directly interacting with NIX 
(proapoptotic Bcl-2 related protein) and Myt1 kinase (negative regulator of G2-M 
transition) 79. Another study has found that STAMP3/TSAP6 interacts with translationally 
controlled tumor protein (TCTP), a protein promoting histamine release, whose secretion 
was induced by the STAMP3/TSAP6 ovexpression  80. 
 
1.5.6  Structural analysis and possible function 
The 6TM domain, shared by all STAMP/STEAP proteins, is flanked by a large N-terminal 
and a short C-terminal domain (Figure 4). Its structure displays similarities to channel and 
transporter proteins 3. Studies undertaken utilizing interactive profile sequence similarity 
search have indicated that the 6TM of the STAMP/STEAP proteins have high sequence 
similarity to the respective domains in nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (Nox) and YedZ protein family members 81. The eukaryotic Nox 
proteins are involved in production of reactive oxygen species (ROS), that contain N-
terminal heme binding transmembrane domain and two C-terminal domains binding flavin 
adenine dinucleotide (FAD) and NADPH 82. In addition to being involved in bacterial 
defense they have been implicated in signal transduction, cancer, mitogenic signaling, 
growth, angiogenesis, and modification of the cellular matrix proteins 81-83. A Yed2 
oxidoreductase family member found in E. coli, has been shown to bind heme and is 
suggested to be involved in electron transfer. Based on these findings it has been 
hypothesized that STAMP/STEAP proteins might be involved in oxidation/reduction 
events that may influence cell signaling, cancer and apoptosis 81. 
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Additionally, the 6TM proteins have been previously implicated in connection with disease 
states. For instance, an ATP-binding cassette (ABC) transporter gene mutation was 
reported to be responsible for Tangier disease 84. In addition the Wilson disease is a result 
of malfunction of the putative copper-transporting P-type ATPase, ATP7B, leading to toxic 
accumulation of copper in the liver and brain 85. This latter protein, ATP7B, in addition to 
the structural similarities seems to share similar function, namely copper transport. 
Recently it was shown that STAMP3/STEAP3, mammalian ferrireductase was critical for 
erythroid iron homeostasis 86. The same group argues that tissue-expression pattern of the 
four murine members of STAMP/STEAP family, STEAP, STAMP1, STAMP3 and 
STAMP2, is relevant to metal homeostasis 87. It was shown that the proteins co-localize 
with transferrin and transferrin receptor, which indicate possible function in iron uptake. 
The same study suggests that STAMP1, STAMP2 and STAMP3 can indeed reduce both 
iron and copper and simulate their cellular uptake in vitro 87. These interesting findings as 
well as the ones described above, establish the basis for further functional studies of the 
STAMP/STEAP family. 
 
1.6 Human STAMP2 
 
Earlier work conducted in our laboratory led to the identification and cloning of the 
STAMP2 gene while searching for homologues of the previously identified STAMP1 gene 
3. STAMP2 gene is around 26 kb long, consists of five exons and four introns (Figure 5a) 
and is located on chromosome 7 close to two other members of this family, STEAP and 
STAMP1 (Figure 5b). Its amino acid sequence is 64% conserved and 44% identical to that 
of STAMP1. Additionally it has 78% amino acid sequence identity to TIARP (mouse 
homologue) as well as significant similarity to pHyde (rat homologue of STAMP3)(Figure 
4). While its C-terminal contains the 6TM domain, three protein motifs have been 
identified in its N-terminal domain. These are: dinucleotide-binding domain, F420-
dependent NADP oxidoreductase motif and a motif resembling the pyrroline 5-carboxylate 
reductase involved in amino acid metabolism and transport 3. STAMP2 mRNA has been 
shown to be strongly expressed in placenta, lung, heart and prostate tissues (Figure 6a). Its 
expression in the LNCaP cells was increased upon androgen stimulation (Figure 6b), in 
contrast to other STEAP protein family members.  Northern blot analysis showed that no 
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STAMP2 expression could be detected in the AR-negative cell lines, DU 145 and PC-3, or 
other tissue cancer cell types tested. The subcellular distribution of the GFP-tagged 
STAMP2 protein included: Golgi complex, trans-Golgi network, plasma membrane, 
vesicular-tubular structures and endoplasmic reticulum. Moreover, the rapid trafficking of 
the protein localized to vesicular-tubular structures in the cytosol and colocalisation with 
the EEA1 might suggest the potential function in endocytic and secretory pathways 3. 
Further experiments showed that STAMP2 mRNA expression was significantly 
upregulated in prostate tumors, compared to normal glands. Overexpression of STAMP2 in 
the STAMP2 negative PC-3 cell line resulted in increased number and size of cell colonies, 
while overexpression of STAMP2 in COS7 and DU 145 increased cell growth 3. These 
results indicate that one function of STAMP2 may be involved in the development of the 
prostate carcinoma, which makes it a potential therapeutic target and biomarker for this 
disease 3. The murine homolog of the same protein, TIARP, has been implicated in the 
regulation of metabolic homeostasis, as well as in the pathology of insulin-resistance 
73,76,77. Another report suggests that the TIARP functions as a metaloreductase 87. With 
respect to studying the genesis and physiology of the PCa, the fact that STAMP2 
expression is regulated by androgens in the human prostate is particularly relevant. 
However, more studies are necessary in order to further elucidate and understand the 





Figure 5.   Schematic structure and location of the STAMP2 gene 
a) Sites of the exons (boxes) and introns are shown and the position of predicted start and stop 
codon are indicated by arrows (black and gray respectively). b) The relative location of the three 
STAMP/STEAP family members on chromosome 7 are shown. The telomeric and centrometic ends 
of the chromosome, and location of the bacterial artificial chromosome (BAC) clones and the 
distance between the genes are indicated. (Figure taken from 3)           
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Figure 6.   Characterisation of the STAMP2 gene expression 
a) Northern blot was probed with STAMP2 or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) cDNA. The lanes represent mRNA from: 1. heart, 2. brain, 3.placenta, 4. lung, 5.liver, 6. 
skeletal muscle, 7.kidney, 8. pancreas, 9. spleen, 10. thymus, 11. prostate, 12 testis, 13. ovary, 14. 
small intestine, 15. colon, 16. peripheral blood leukocyte. The stronger hybridization observed for 
GAPDH in  lanes 1. and 6. its due to its higher expression in these tissues. b) Northern analysis of 
the total RNA represents the time course of STAMP2 mRNA accumulation in LNCaP cells treated 




1.7 Transcription studies: computational and 
experimental 
 
1.7.1  Computational analysis 
Each of tens of thousands of genes in the eukaryotic cell has a unique expression pattern. 
Most of the information about a particular gene’s expression program is encoded in its 
DNA sequence. Thus, in order to understand the mechanism that guides transcription of 
each gene, it is essential to identify and characterize its promoter, enhancer/silencer 
elements (cis-acting elements) and the transcription factor (trans-acting factor) binding 
sites that they contain 88. Easily accessible bioinformatics tools, developed within the last 
three decades, allow for the quick wide-scale analysis of the eukaryotic genes. This 
involves, for example, detection of putative transcription factor (TF) binding sites (TFBS) 
in the assumed promoter region. Moreover, a genome-wide prediction of TFBPs is carried 
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out by software on a query sequence that can span over many kilo bases. For these analysis, 
in addition to complicated algorithms, it was necessary to create electronic databases with 
consensus sequences for promoter elements and TFBSs 89. Such databases are made based 
on the collection of experimentally defined TFBPs and promoter elements in a set of co-
regulated genes. The Gene2Promoter (i) program found at the Genomatix webpage (Table 
1), is an example of an online software tool that has been designed to identify putative 
promoters in query sequences. This is carried out by identifying the locus in a query 
sequence and subsequently listing all alternative transcripts and promoters for that locus. It 
can also analyze the localized genes and promoters using ElDorado (ii), Genomatix 
genome annotation. MatInspector (iii) is another Genomatix software tool utilizing a large 
matrix, and matrix family (iv), library, for the TFBS in order to locate matches in the query 
DNA sequence 90,91. 
 
1.7.2   Experimental analysis 
Bioinformatics has now become an essential and integral area of molecular, cell biological, 
and biochemical research. Nevertheless, it should be recognized that bioinformatics 
provides predictions which need to be experimentally supported as false positive and false 
negative results are possible.  Thus laboratory experimentation need to be utilized in order 
to gain empirical evidence that would supplement the hypothetical computational analysis 
provided by bioinformatics. For example, to validate promoter localization of a gene, 
primer extension analysis can be used to reveal the actual transcription start site and help to 
localize the core promoter region (reviewed in 89). DNA-pull down strategies, including 
chromatography and electrophoretic mobility shift assay (EMSA), are effective methods 
for identification and isolation of the sequence-specific DNA binding factors from nuclear 
extracts (reviewed in 89). EMSA is based on the fact that a protein-bound labeled DNA 
fragment will migrate slower on the gel compared to the control unbound labeled DNA 
fragment. Deoxyribonuclease I (DNase I) footprinting assay is another method for 
detecting TFBSs at a single base pair resolution (reviewed in 89). It utilizes the DNase I to 
cleave radioactively labeled DNA. Followed by electrophoresis, the exact fragments 
protected from digestion by bound proteins, can be revealed. Another experimental 
procedure, ChIP assay, examines the protein-chromatin interactions in vivo (reviewed in 
89). In this method one first cross-links the proteins attached to DNA with formaldehyde. 
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After shearing the DNA, specific antibodies are used to pull down the TFs of interest and 
following reversal of crosslinking the immunoprecipitated DNA fragment can be amplified. 
These methods are able to detect specific TFs that physically interact with a particular 
DNA sequence. In order to examine the functional relevance of these interactions and to 
detect promoter and/or enhancer activity in a chosen DNA fragment, reporter gene assays 
can be applied (reviewed in 92). As a general rule, the DNA fragment containing the 
putative promoter is cloned upstream of a reporter gene, of which expression can easily be 
detected and quantified. Such analysis has been automated and a range of different reporter 
gene vectors are available. Some of these are designed to detect and study promoters, 
others to work with enhancers. For additional evidence, site directed mutagenesis can be 
utilized. By mutating the potentially important cis- and trans-acting elements, in 
combination with above described laboratory techniques, one can verify their importance 





1.8 Aim of study 
 
The STAMP/STEAP protein family includes novel genes, whose function is not fully 
known. As detaile above, it has been previously shown that expression of the human 
STAMP2 mRNA is significantly upregulated in prostate tumors compared to normal glands 
and that STAMP2 overexpression can induce cell proliferation 3. In addition, STAMP2 
expression is stimulated by androgen treatment and it is detectable only in AR positive 
LNCaP cells. To get a better understanding of STAMP2 function, it is essential to study its 
transcriptional regulation. The work described in this thesis is aimed at identifying and 
cloning the STAMP2 promoter and 5’-flanking sequences and the factors that are involved 
in STAMP2 transcription. Furthermore, work is presented which aimed to determine how 
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Prostate cancer is the most common non-skin cancer and the third leading cause of cancer 
death in men in developed countries. No effective cure has yet been found to treat the 
hormone refractory state of PCa. In addition to study the actions of the AR, a focus has 
been directed towards identifying androgen-regulated genes as potential biomarkers and 
therapeutic targets for the disease. hSTAMP2 is one of these genes identified in our 
laboratory when searching for genes differentially expressed in the early stages of prostate 
cancer. Our previous studies have shown that its mRNA is highly expressed in the prostate 
tissue and upregulated in prostate tumor samples. Moreover, its overexpression increased 
colony formation and cell growth of PCa cell lines, suggesting a possible function in 
prostate pathology. Furthermore, its mRNA expression appeared to be androgen stimulated. 
These results suggest a possible androgen –dependent cis-regulatory elements located in 
the hSTAMP2 5’flanking sequence. Computational analyses reveal a number of 
transcription factor binding sites and androgen response elements (AREs) that may be of 
importance for the hSTAMP2 gene regulation. Reporter gene assays show the different 
effect that androgen has on the hSTAMP2 putative promoter activity in two different PCa 
cell lines. The complexity of the androgen regulation of hSTAMP2 expression is supported 
in experiments where LNCaP cells were treated with CHX, suggesting the requirement of 
de novo protein synthesis for the AR mediated hSTAMP2 gene regulation. Additional 
studies are needed to identify potential AREs located in the sequences further upstream and 





PCa is the most common non-skin cancer and the third leading cause of cancer death in 
men in developed countries 1. Development and growth of both the prostate and PCa 
depend on androgens that, after entering the cell, bind to and activate the AR. The ligand-
bound AR then enters the nucleus where it interacts with AREs in the chromatin. In concert 
with recruited coregulators, it can either activate or repress expression of its target genes 2. 
In the early stages, PCa relies on androgen for growth and can therefore regress in response 
to hormonal therapy. Androgen ablation by surgical castration and use of various inhibitors 
and antiandrogens, have been the critical therapeutic options for the PCa treatment so far 3. 
However, in spite of the good initial therapeutic response, in most cases the tumors 
eventually recur as androgen-independent, adopting a lethally resistant phenotype. Since no 
efficient cure has been found to battle the hormone refractory state of PCa, much effort has 
been put into understanding the molecular mechanisms that govern androgens’ effect on 
prostate physiology and pathology. It has been shown that upon progression of the PCa to 
hormone independence, AR signaling is still active and androgen-response genes are 
upregulated in a ligand-independent manner 4. AR amplification, both at gene and protein 
level, is one of the cellular events that have been observed in prostate tumor progression. In 
addition, increased stability of the AR, as well as activation and nuclear localization has 
been proposed to account for maintained signaling in PCa. Furthermore, AR mutations, 
changes in the cellular level of AR coregulators, as well as overexpression of growth 
factors are thought to alter AR’s ligand sensitivity and specificity (reviewed in refs. 5 and 
6). Thus all these proposed events, leading to amplification of the AR signaling under low 
testosterone level, point out that AR is a potential target in treating the androgen 
independent state of the PCa. 
 
In quest for therapeutic targets and biomarkers for the disease, androgen target genes have 
been another important field of study. Development of methods for the wide scale gene 
expression analysis, both computational and laboratory, has contributed to identification of 
a large number of potential androgen regulated genes. Some of these are used as PCa 
markers. PSA, a member of the kallikrein protein family, is the best characterized androgen 
target gene and has been utilized in screening of patients as an indicator for the prostatic 
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disease 7. Secreted PSA has been shown to be directly regulated by the androgen receptor 
that binds at multiple AREs located in the proximal promoter and distal enhancer of the 
PSA gene 8-10. KLK2, a member of the same protein family, is another example of AR 
target genes of which regulatory elements have been well studied 11. NKX.3.1 and KLK4 
are two other proteins highly expressed in prostate that are also regulated by androgens 12-
14. In addition to the direct effect of DNA-bound AR on gene expression, DNA binding-
independent action of  AR, so called “triggering of coactivators” has been reported 15. 
Another study suggests evidence for the ligand-independent and DNA-binding independent 
AR transcriptional activation of the PSA gene 16. Alternatively, AR is able to affect 
expression of a gene indirectly by regulating mRNA synthesis of its transcriptional 
regulators. Moreover, nonclassical action of the AR, where the AR can regulate CREB-
mediated gene expression via the MAPK pathway, has been reported in Sertoli cells 17. 
Whether it binds directly to regulatory elements in DNA, or acts indirectly through other 
proteins, AR together with its target genes remain as leading potential factors in prostate 
pathophysiology. 
 
While searching for highly expressed prostate tissue genes, a novel protein, STEAP, was 
identified. The STEAP protein was shown to be located at the cell-cell junctions of the 
prostate epithelial cells 18. Later, another closely related protein family, STAMP, was 
identified 19. So far identified family members include STAMP1/STEAP2, 
STAMP2/STEAP4/TIARP (mouse homologue) and STAMP3/TSAP6/pHyde (rat 
homologue) 18-25. Structural computational analysis revealed that all these proteins 
(including STEAP) contain a 6TM domain, flanked by N- and large C-terminal domain and 
that their structure carries similarities to that of the channel and transporter proteins 20,26. 
Based on sequence similarity searches it was shown that the 6TM of the STAMP proteins 
is a homologue to the respective domains in Nox and YedZ protein family members 
leading to the suggestion of the possible function in an electron transfer system 26. 
Furthermore, studies of subcellular localization and biochemical assays have recently 
demonstrated that the murine STAMP1/STEAP2, STAMP2/STEAP4 and 
STAMP3/STEAP3 can reduce both iron and copper and mediate their uptake in vitro 27,28.  
These findings and the fact that the 6TM proteins have previously been suggested to play a 
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role in disease states  resulted in the hypothesis that STAMP proteins are important for both 
normal prostate and PCa development 29,30. 
 
While searching for genes differentially expressed in early PCa, our group cloned a gene 
that had high sequence similarity to the previously identified STAMP1 and named it 
STAMP2 20. In addition to STAMP1, its amino acid sequence shows high similarity to the 
mouse homologue of STAMP2, TIARP, and the rat homologue of STAMP3, pHyde. There 
is evidence suggesting that this novel protein may be important for both normal prostate 
function and PCa progression. Firstly, STAMP2 mRNA was highly expressed in the 
prostate tissue. Secondly, while its expression could not be detected in a number of AR- 
negative cell lines, its expression was observed in the AR-positive LNCaP cells and was 
strongly stimulated by androgens. STAMP2 mRNA was also shown to be highly 
upregulated in prostate tumor samples versus normal prostate tissue.  In addition, ectopic 
expression of STAMP2 in STAMP2-negative PCa cell lines increased colony formation 
and cell growth. Further experiments demonstrated that STAMP2 is localized to the plasma 
membrane and most of the intracellular membrane structures suggesting a possible function 
in endocytic and secretory pathways 20.  
 
The prostate is a major secretory organ that is dependent on androgens for normal 
development as well as progression to carcinoma. The STAMP2 findings described above 
indicate that STAMP2 is a potential AR target gene which needs to be elucidated.  It is also 
important to investigate whether the AR directly binds to regulatory sequences in the 
STAMP2 locus. In the study presented in this thesis the STAMP2 5’flanking sequence has 









2.2 Materials and methods 
 
2.2.1  Materials 
Agar and Luria-Bertani (LB) were purchased from Becton, Dickenson and Company. 
AquaPhenolTM  was purchased from Q-BIOgene and ethanol and isopropanol were obtained 
from Arcus Kjemi AS. Ethidium bromide was purchased from Merck KGaA, agarose  
standard and 5’-bromo-4-chloro-3-indolyl-β-D-glactopyranoside (X-gal) were purchased 
from Saveen Warner AB. Glutaraldehyde was obtained from Electron Microscopy Sciences 
and hydroxymethyl aminomethane (TRIS), sodium chloride (NaCl) and sucrose were 
purchased from BDH. Activated charcoal, adenosine 5’-triphosphate (ATP), actinomycin D 
(ActD), ampicillin, chloramphenicol, bovine serum albumin (BSA), chloroform, 
cycloheximide (CHX), kanamycin, lysozyme, magnesium acetate, magnesium chloride 
(MgCl2 ), octyl phenoxy polyoxy ethanol (Triton-X 100), potassium ferricyanide, 
potassium ferrocyanide, ribonuclease A (RNAse A) and sodium acetate (NaAc) were 
obtained from Sigma-Aldrich. The CTB-167B5 bacterial artificial chromosome (BAC) 
clone (AC003991), DH10BTM electro competent Escherichia coli, dithiothreitol (DTT), D-
luciferin free acid with sodium salt, glycerol, LipofectamineTM 2000, One Shot® MAX 
Efficiency® DH5αTM -T1R chemically competent E. coli, OptiMEM® I, pCMV-β-gal, 
pCR®-Blunt II-TOPO® vector, pUC18, pUC 19, SuperscriptTM II Reverse Transcriptase 
and TRIzol® Reagent were purchased from Invitrogen. JETStar 2.0 Plasmid Midiprep Kit 
was obtained from Genomed, The E.Z.N.A.TM Plasmid Mini Kit II was purchased from 
Omega Bio-tek and QIAEX®II Gel Extraction Kit was obtained from Qiagen. pGL2-Basic 
Vector, rRNasin® RNase Inhibitor and RQ1 RNase-Free-DNase were purchased from 
Promega. PhusionTM High-Fidelity DNA Polymerase and DyNAzymeTM II DNA 
Polymerase were obtained from Finnzymes. Deoxyribonucleosine-5’-triphosphates 
(dNTPs), T4 DNA ligase, 2-Log DNA ladder and all restriction enzymes with their 
respective buffers were purchased from New England Biolabs. RPMI 1640, L-glutamine, 
trypsin/EDTA and penicillin/streptomycin were purchased from Bio-Whittaker-Cambrex, 
and fetal calf serum (FCS) were obtained from from PAA GmgH. The MycoAlert® 
Mycoplasma Detection Kit was purchased from Lonza. FuGENE 6 Transfection Reagent, 
LightCycler® 480 SYBR Green I Master and LightCycler® 480 Multiwell Plates 96 were 
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obtained from Roche Diagnostics. The Bio-Rad Protein Assay was purchased from BIO-
RAD, and methyltrienolone (R1881) was purchased from Perkin ElmerTM life sciences. 
pSG5 was obtained from Stratagene and the pSG5-AR 31 and -285PB-LUC 32 plasmids 
have been described earlier. Oligo dTs and all primers were manufactured by Sigma-
Genosys. The human prostate cell lines LNCaP, DU 145, and PC-3 were obtained from the 
American Type Culture Collection (Rockville, MD, USA). 
 
2.2.2  Methods 
2.2.2.1 Theoretical promoter analysis 
The 5’-flanking sequence of the human (AF423422) and mouse (BC006651 and 
AJ319746) STAMP2 genes were scanned for putative promoters using the Gene2Promoter 
software (Genomatix). Transcription factor (TF) binding sites were predicted by the 
MatInspector (Genomatix) software 33. As exclusion criterions, core sequence similarity 
was chosen at 1.00 and matrix similarity above 0.8. Other bioinformatics tools (Table 1) 
were then used for further promoter and TF binding sites analysis. 
 
Table   1.   List of the bioinformatics tools used in promoter and TF binding sites analysis 
Software/Database Web page address 
Gene2Promoter and MatInspector (Genomatix) http://www.genomatix.de  
Promoter 2.0 Prediction Server http://www.cbs.dtu.dk/services/promoter  
Neutral Network Promoter Prediction http://www.fruitfly.org/seq_tools/promoter.html  
Softberry Promoter Prediction http://www.softberry.com/berry.phtml   
PROSCAN Version 1.7 http://www-bimas.cit.nih.gov/molbio/proscan  
TFSEARCH http://www.cbrc.jp/research/db/TFSEARCH.html 
Transcription Element Search System http://www.cbil.upenn.edu/cgi-bin/tess/tess  




2.2.2.2 Reporter vector construction 
2.2.2.2.1 Fragment amplification 
The CTB-167B5 bacterial artificial chromosome (BAC) clone (AC003991) was amplified 
in E.coli bacteria and purified using the JETSTAR 2.0 Plasmid Miniprep Kit according to 
the manufacturer’s instructions (Genomed). Primers (Table 2) were designed using the 
Primer3 program and blasted to known sequences (NCBI) to ensure specific binding. 
Fragments of the human STAMP2 (hSTAMP2) 5’flanking sequence were amplified by 
polymerase chain reaction (PCR) from the BAC clone described above. 0.02U PhusionTM 
High-Fidelity DNA Polymerase (Finnzymes), 200μM of dNTPs, 0.5mM of each primer 
and 140 ng template were used in 50μl reactions. The PCR program consisted of: 30 s at 
98°C, 20 cycles (denaturation: 10 s at 98°C, annealing: 30 s at 55°C, and elongation: 30 
s/kb at 72°C) followed by a 10 min final extension step at 72°C. The size and quantity of 
the products were examined on a 1% agarose gel. The following putative STAMP2 
promoter fragments were generated using the primers indicated in brackets (referring to 
Table 2), position +1 refers to the first bp (basepair) of the 5’ untranslated region (UTR): -
5674 to +185 (primer pair 7 and 8), -4076 to +185 (primer pair 3 and 6), -2094 to +185 
(primer pair 5 and 6), named 6kb, 4kb and 2kb respectively, and -5674 to -2061(primer pair 
1 and 4), -4076 to -2061 (primer pair 3 and 4), -5674 to -4055 (primer pair 1 and 2), named 
F1-R2, F2-R2 and F1-R3 respectively. Fragments 6kb, 4kb and 2kb contained the predicted 













Table  2.  Primers for the hSTAMP2 promoter region amplification  
No
. 
Name Sequence (5’→3’)* Position*
* 
Annealin
g T (°C) 
1 hStamp2F1 gacgcg|tcgacgcacaaattgcctggactggaatt 
           SalI -5674 55 
2 hStamp2R1 cccgcg|gatcctgccttccttgcctgctctagtc 
         BamHI -4055 55 
3 hStamp2F2 gacgcg|tcgacactagagcaggcaaggaaggca 
          SalI -4076 55 
4 hStamp2R2 cccgcg|gatccggtttctttacaccagcatcacca 
         BamHI -2061 55 
5 hStamp2F3 gacgcg|tcgactggtgatgctggtgtaaagaaacc 
          SalI -2094 55 
6 hStamp2R3 cccgcg|gatccctgttcttcagtgcgatgggc 
         BamHI +185 55 
7 hStamp2F1new ggtac|cgcacaaattgcctggactggaatt 
  KpnI 
-5674 55 
8 hStamp2R3new c|tcgagctgttcttcagtgcgatgggc 
  XhoI 
+185 55 
9 hStamp2F2_int tttggtggtgcacaacatct 
 
-597 55 








12 hStamp2F1_int ttgcttcctggtctgtgttg 
 
-4951 55 
13 hStamp2R2_int aggcctagagccagtgttca 
 
-3480 55 
14 pGL2b.F tgtatcttatggtactgtaact 
 
  
15 pGL2b.R ctttatgtttttggcgtcttcc 
 
  
* Sequences (1-13) designed using Primer3 software: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 




Amplified fragments were cloned into the pCR®-Blunt II-TOPO® vector according to the 
manufacturer’s instructions with some modifications (Invitrogen). 4μl of PCR product and 
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1μl of 1:5 diluted vector were used, the reactions were then incubated at room temperature 
over night. One Shot® MAX Efficiency® DH5α -T1R chemically competent E. coli cells 
were transformed with 5μl TOPO reaction following the manufacturer’s protocol and the 
transformation reaction was spread on LB plates containing 50μg/ml kanamycin. The 
transformation efficiency was determined by counting the number of colony forming units 
(CFU) using pUC19 as a positive control.  
 
2.2.2.2.3 Screening of putative positive transformants 
 
Putative positive colonies containing the transformed constructs were screened by whole-
cell PCR using primers from Table 2. Bacterial clones were added to a master mix 
comprised of 200μM of dNTPs, 200μM of primers and 2U DyNAzymeTM II DNA 
Polymerase (Finnzyme) in a total volume of 25μl. The PCR conditions were as follows: a 
10 min cell lysis step at 95°C, followed by 35 cycles (30 s at 95°C, 35 s at 55°C and 1 min 
at 72°C ) and a final extension step (6 min at 72°C). Positive clones were then grown in 
selective LB medium, containing 50μg/ml kanamycin, over night at 37°C. For diagnostic 
restriction enzyme digest, small scale plasmid DNA purification (STET miniprep) was 
used (Molecular Cloning, 3rd edition, Sambrook and Russel). Cells from 1.5ml overnight 
bacterial cultures were pelleted by centrifugation and resuspended in 400μl of STET (8% 
sucrose, 0.5% Triton X-100, 50mM EDTA, pH 8.0 and 10mM Tris-Cl, pH 8.0). 10μl of 
1mg/ml RNAse and 30μl of 10mg/ml lysozyme were then added and mixture incubated on 
ice for 2-3 min. The tube was placed in boiling water for 60 s and then immediately put on 
ice. After 15 min centrifugation at +4°C (13000 rpm) the mucoid pellet was removed, the 
DNA precipitated with 400μl pre-chilled (-20°C) isopropanol and centrifuged as before. 
The DNA pellet was then washed twice with 70% ethanol and resuspended in MQ-water 
by a 15 min incubation step at 65°C. The size and orientation of the inserts were confirmed 
by diagnostic restriction enzyme digestion. 
2.2.2.2.4 Generating pGL2-Basic reporter constructs 
The 2kb forward and reverse putative STAMP2 promoter constructs, as well as the 4kb 
forward, the 6kb forward and 6kb reverse constructs were digested with restriction 
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enzymes from the respective TOPO vectors and cloned into the multiple cloning site 
(MCS) of the pGL2-Basic vector (Promega). The plasmids were amplified in E.coli and 
purified using the E.Z.N.A.TM Plasmid Mini Kit II (Omega Bio-tek). 5μg of both inserts 
and pGL2-Basic vector digested with KpnI and XhoI were separated on a 1% agarose gel. 
The fragments were then excised and gel extracted using the QIAEX®II Gel Extraction Kit 
according to the manufacturer’s instructions (Qiagen). The concentration of purified DNA 
was then estimated by gel electrophoresis, comparing the intensity of the fragment to 1 μg 
of a 2-Log DNA ladder. The inserts were subsequently ligated into the pGL2-Basic vector 
using T4 DNA ligase according to the manufacturer’s instruction (New England Biolabs). 
Between 200 and 600 ng insert was used for each reaction and the ligation was carried out 
at 16°C over night. The ratio of vector to insert used in the reaction was 1: 3. After 
transforming 2μl ligation reaction into 20μl DH10B electro-competent cells at 1.3 Volt and 
200 Ω, the bacteria were shaken for 1 hour in antibiotic-free LB medium at 37°C and then 
spread out on 100μg/ml ampicillin containing LB plates. Putative positive colonies were 
screened by whole cell PCR and STET miniprep as described in section 2.2.2.2.3. For 
transfection experiments, the constructs were purified using the JETSTAR 2.0 Plasmid 
Midiprep Kit. Concentration and purity of the DNA were measured with a Lambda25 
spectrophotometer (Perkin ElmerTM life sciences) at 260 and 280nm.  The three forward 
constructs were sequenced by ABI-lab, placed in the Department of Biology and Molecular 
Biosciences, University of Oslo, using primers from Table 2.  
 
2.2.2.3 Cell culture 
The human prostate cancer cell lines LNCaP, DU 145, and PC-3 were routinely maintained 
in RPMI 1640 supplemented with 10% fetal bovine serum (FCS). All media used in the 
experiments were supplemented with 50U/ml penicillin, 50μg/ml streptomycin and 200 nM 
L-glutamine, if not indicated differently. The cells were incubated at 37°C in a humidified 
5% CO2, 95% air incubator. The culture medium was changed every 2-3 days. The passage 
number of LNCaP cells used in experiments was between 16 and 23. The MycoAlert® 
Mycoplasma Detection Kit (Lonza) was used to test cells for mycoplasma contamination.  
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2.2.2.4 Cell transfection and Reporter Experiments 
2.2.2.4.1 DU 145 and PC-3 cells transfection 
DU 145 and PC-3 cells were plated out in 6-well plates at density of 1.5×105 cells in 2ml 
10% FCS- RPMI 1640 per well and grown until they reached 70% confluence. 2-3 hours 
prior to transfection, the medium was removed, cells rinsed with Phosphate buffered saline 
(PBS), pH 7.4 and 2ml 0.5% CT-FCS RPMI 1640 was added. The transfection was carried 
out according to the manufacturer’s instructions (Roche Diagnostics). 3μl FuGene6 reagent 
diluted in 100 DMEM was used per well. The following constructs were used for 
transfections (amount of DNA given as ng per well). 150ng of -285PB-LUC vector was co-
transfected with 15ng pSG5-AR vector. Similar molar ratios of empty pGL2-Basic 
(280ng), pGL2-Basic-6kbRev.( 580ng), pGL2-Basic-2kbForw.( 400ng), pGL2-Basic-
4kbForw.( 500ng) and  pGL2-Basic-6kbForw (580ng) were each co-transfected with either 
pSG5-AR (75ng for DU 145, 30ng for PC-3 cells) or molar ratio of empty pSG5 (41ng for 
DU 145 cells, 16,5ng for PC-3 cells). pUC18 plasmid (carrier DNA) was added to each 
DNA mix to bring it up to a total concentration of 1μg DNA per well. After transfection, 
the cells were incubated at 37°C over night. The following morning, the medium was 
removed and replaced with 1ml 0.5% CT-FCS RPMI 1640 with either 10-8 M R1881 or 
vehicle (ethanol) and incubated for another 48 hours. All transfections were carried out in 
triplicates and each experiment was repeated at least twice. β-gal assay was used to assess 
transfection efficiency (Section 2.2.2.4.3).  
 
2.2.2.4.2 LNCaP cells transfection 
LNCaP cells were plated out in 2ml 10% FCS containing RPMI 1640 medium at a density 
of 2×105 cells per well in 6-well plates and grown until they reached 70 % confluency. 
Transfection of the same reporter constructs, as used for other cell lines, was carried out 
with FuGene6 and cells incubated as described above. No AR plasmid was co-transfected, 
since LNCaP is an AR-positive cell line. pUC18 was used as a carrier DNA to raise DNA 
amount to 1μg per well. 
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LnCaP cells were also transfected using LipofectamineTM 2000, according to 
manufacturer’s protocol (Invitrogen). Cells were transfected in 0.5% CT-FCS antibiotic 
free medium. The same amounts of constructs were used as described above and pUC18 
was used to raise the DNA amount to 4μg per well. OptiMEM I was used to dilute both 
transfection reagent and DNA. All transfections were carried out in triplicates. β-gal assay 
was used to assess transfection efficiency (Section 2.2.2.4.3).  
 
2.2.2.4.3 β-galactosidase (β-gal) assay 
LNCaP cells were transfected with 1μg pCMV-βGAL vector per well in 6-well plates using 
FuGene6 or Lipofectamine 2000 and incubated, as described above. The media was 
removed; cells washed in PBS and then fixed for 5 minutes with 1.5ml 0.5% 
glutaraldehyde in PBS. After fixing the cells and washed with PBS, 1.5ml β-gal buffer (1× 
PBS, 10mM potassium ferricyanide, 10mM potassium ferrocyanide, 4.5M magnesium 
chloride, 1mg/ml X-GAL) was then added and the cells were incubated at 37°C over night. 
After wash with PBS, transfected cells (blue) were counted under a light microscope to 
determine the transfection efficiency (ratio of transfected cells / total number of cells).  
2.2.2.4.4 Luciferase measurement 
Transfected cells were rinsed with PBS and 150μl cell lysis buffer (25 mM Tris-HCL, pH 
7.8, 2mM DTT, 10% glycerol, 1% Triton-X) was added to each well. The plates were then 
shaken for 5 min at room temperature. Cell lysates were transferred to eppendorf tubes and 
spun down for 2 min at 4°C (13000 rpm). 10μl supernatant and 50 μl of luciferase reaction 
mix (100mM Tris-O-acetate, pH 7.8, 10mM Magnessium-O-acetate, 1mM EDTA, 0.2mM 
D-luciferin, 2mM ATP) was used for measurement of luciferase activity. The luminescence 
of each sample was counted using a Victor2 TM 1420 Multilabel Counter (Perkin ElmerTM 
life sciences) and recorded as counts per seconds (CPS). The Bio-Rad Protein Assay 
reagent was used to estimate total protein concentration in the cell lysates to normalize for 




2.2.2.5 Inhibition of transcription and translation experiments 
2.2.2.5.1 ActD / CHX treatment  
LNCaP cells were plated out in 10-cm culture plates. After reaching 40% confluence, the 
following starvation protocol was applied: after removal of 10% FCS medium, cells were 
washed with PBS and 2% CT-FCS medium was added, after 48h the medium was changed 
to 0.5% CT-FCS medium and cells were starved for 24h. Cells were then pre-treated with 
either ActD (1μg/ml), CHX (1μg/ml), or vehicle (ethanol) for 60 min, followed by 24 h 
treatment with R1881 (10-8 M), or vehicle (ethanol). The cells were then washed with PBS 
and harvested by cell scraping. Two independent experiments in triplicate were carried out 
for each experiment. 
2.2.2.5.2 RNA isolation 
Total RNA was extracted using TRIzol® Reagent according to the manufacturer’s 
instructions. The extracted RNA was treated with RQ1 RNase-Free-DNase (2U per 10  μg 
RNA) at 37°C for 60 min (Promega), followed by 3M sodium acetate (pH 5.2) and ethanol 
precipitation. RNA concentration and purity were measured with Lambda25 
spectrophotometer (Perkin Elmer Life Sciences) at 260 and 280nm. To asses RNA quality, 
2μl was run on 1 % agarose gel for 10 min at 200V. 4-5μg RNA was then reverse-
transcribed by SuperScriptTM II reverse transcriptase (Invirogen). Oligo-dTs were used as 
primers and rRNasin® RNase Inhibitor was added to inhibit potential RNAses. The quality 
of the cDNA and no RT negative controls were checked by PCR using hTCTP primers 
(Table 3). 
2.2.2.5.3 qRT-PCR 
Quantitative real time PCR (qRT-PCR) analysis were performed using LightCycler® 480 
(Roche Diagnostics) in multiwell plates. Lightcycler® 480 SYBR Green I Master, 0.5μM 
of each primer and 2 μl of diluted cDNA template were used in 10μl PCR reactions (Table 
3). The PCR program was comprised of a denaturation step (5 min at 95°C) and 45 cycles 
of: denaturation (5 s at 95°C), annealing (20 s at respective annealing temperature) and 
extension (30 s at 72°C). The PCR was carried out in duplicates for each sample and a 
template-free reaction was included for each primer pair as a negative control. For 
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normalization, the housekeeping gene GAPDH was amplified in parallel with each sample 
(Table 3) to compensate for quantity variation between the samples.  To exclude non-
specific PCR by-products and reveal presence of possible primer dimers, melting curve 
analysis was performed: 5 s at 95°C, 1 min at 65°C followed by continuous fluorescence 
measurement between 65°C and 97°C. Finally a cooling step (10 s at 40°C) was applied. 
The crossing point (CP) values were calculated by the software as the cycle number at 
which the increase of the product became logarithmic. Standard curves of each primer pair 
were used as standards. One negative and one positive (R1881 treated cells) reaction for 
each primer pair were run on a 1% agarose gel to verify product size. 
 
Table  3.  Primers and conditions used in qRT-PCR 
Respective 
gene 







F: gtcagtggtggacctgacct  







F: ccctgagcacccctatcaac  
PSA 







F: ggcctgggagtctcttgactccactac  







F: atgacagcaaagccaagcaa  







F: atggaaaacgaattgttctgctcg  







F: gaggggaagatggtcagtagg  








2.2.2.6 Data analysis 
The data was analyzed with Microsoft Office Excel 2003 software. Statistical analyses 
were performed using the Student’s one-tailed t-test, where P values of P<0.05 and P<0.01 




2.3.1 Prediction of hStamp2 promoter and TF binding sites 
To predict the location of the putative promoter of STAMP2, about 6 kilo base (kb) pairs of 
the hSTAMP2 gene (AF423422) 5’- flanking region was used as a query sequence in the 
Gene2Promoter program (Genomatix). The putative promoter region of STAMP2 was 
mapped to chromosome 7 (NC_000007), where the STAMP2 locus and three putative 
promoters were localized. The putative Promoter 1 (Figure 1) aligned with the hSTAMP2 
first exon and was chosen for later analyses. The other two putative promoters identified 
were situated 22.1 and 27.6 kb downstream of the first exon. Previous experiments in our 
laboratory have identified the promoter of the STAMP2 mouse homologue, also called 
STEAP4 (BC006651) or TIARP (AJ319746). The putative human STAMP2 Promoter 1 
has the same localization on the 5’ gene region of STAMP2 as the mouse STAMP2 
promoter identified. Since promoter location and elements are often evolutionary conserved 
between gene homologues, the putative human STAMP2 Promoter 1 was chosen for 












Figure 1.   Sequence of hSTAMP2 putative promoter with predicted TF binding sites   
The putative hSTAMP2 promoter region, identified by Gene2Promoter program, was used as query 
sequence in programs that identify TF binding sites. Sites predicted by more that one software 
(Table 1), are indicated in blue in the figure, each with the number of programs by which it was 
listed. The red, circled factors represent the sites identified by the MatInspector program that are 
common for both human and mouse STAMP2 putative promoter. 
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In order to predict TF binding sites, both the putative human and the mouse STAMP2 
promoters, each about 600 base pairs (bp) long, were analyzed by the MatInspector 
software (Genomatix). When the exclusion criterion core similarity was set to 1 and matrix 
similarity was set to 0.8 or above, the program predicted 62 and 57 TF binding sites on 
both + and - strand for the human and the mouse promoters, respectively. Comparison of 
the hits revealed eight of the same, or belonging to the same family of TF binding sites that 
were situated in similar positions of both promoters. These are presented in Table 4 and 




















































































































Other programs, listed in Table 1, were then used for further screening of the hSTAMP2 
putative promoter. The TF binding sites that were repeatedly predicted by two or three of 
the programs are shown in Figure 1. Since previous findings suggest that hSTAMP2 is an 
androgen target gene 20, the 5’flanking 6kb region of STAMP2 was screened for possible 
































* With respect to the hSTAMP2 first exon base (+1) 










Glucocorticoid receptor, C2C2 zinc finger 
protein binds glucocorticoid dependent to 
GREs, IR3 sites
gagcaacttccaGTCCtgt0.9150.956(+)-1405 to -1387Androgen receptor binding site, IR3 sites
tatgaactgtgtGTCCctc0.9090.956(+)-3189 to -3171Androgen receptor binding site, IR3 sites
caccaccaaatTGTTctta0.8741.000(-)-3367 to -3349Progesterone receptor binding site, IR3 sites
tctgtaaagagtGTGCtgc0.8620.833(+)-4337 to -4319
Glucocorticoid receptor, C2C2 zinc finger 
protein binds glucocorticoid dependent to 
GREs, IR3 sites
tttgcacatcttGTTCttt0.9611.000(+)-5430 to -5412Androgene receptor binding site, IR3 sites
attaatagagaTGTTcttt0.8431.000(-)-5505 to -5487Progesterone receptor binding site, IR3 sites
ataatacttccaGTACtaa0.9150.869(+)-5640 to -5622Androgen receptor binding site, IR3 sites
Sequence **Matrix sim.
Core 
sim.Str.Position *NR binding site
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2.3.2 Generation of luciferase reporter constructs 
 
In order to obtain experimental evidence for the gene regulatory potential of the 5’-flanking 
sequence, six different fragments upstream of the hSTAMP2 first exon were amplified by 
PCR using sequence specific primers (Table 2 and Figure 2) and inserted into the pGL2-













Figure 2.   Amplification of the putative promoter fragments of the human STAMP2 gene 
Six different length fragments were amplified from the hSTAMP2 5’flanking sequence the using 
primers indicated. The fragments’ names are listed to the right of each fragment. Dashed lines show 
localization of the putative promoter. Localization of the hSTAMP2 first two exons (boxes) and 
first intron are shown. 
 
The PCR-amplified fragments (Figure 2 and Figure 3A) were subjected to a two step 
cloning procedure (Figure 3B). The 2kb, 4kb and 6kb putative promoter fragments were 
cloned into the pCR®-Blunt II-TOPO® vector. The 5’-3’ (forward) and the 3’-5’ (reverse) 
of the 2kb fragment, the 4kb forward and 6kb forward and reverse fragments were then 
cloned into the Kpn1 and XhoI site of the pGL2-Basic Vector. Sequencing of the 2kb and 
4kb in the pGL2-basic vector confirmed their correct amplification and cloning. 
Sequencing of the 6kb in the pGL2-basic vector confirmed correct orientations and at least 
93% correct sequence. The remaining ~ 400 bp of the 6kb fragment that could not be 





















Figure 3.   Construction and cloning of the luciferase reporter pGL2-Basic vector constructs 
a) The correct size of each fragment was confirmed by running 5μl of the total 50μl PCR reaction 
by electrophoresis and comparing the size to the molecular marker (M). b) A two-step cloning 
strategy was used to generate the reporter gene constructs. (1) 2kb, 4kb and 6kb fragments were bi-
directionally inserted into the pCR®-Blunt II-TOPO® vector. Next, 2kb forward and reverse, 4kb 
forward and 6kb forward and reverse clones were selected, inserts cut out with the KpnI and XhoI 
restriction enzymes and (2) inserted into the pGL2-Basic Vector cut with the same enzymes, 
upstream of the luciferase gene. The diagrams of both vectors are obtained form the manufacturers’ 




The remaining amplified fragments, F1-R2, F2-R2 and F1-R3 (Figure 2 and 3A), none of 
which contained the predicted promoter, was designed for cloning into the pGL2-Promoter 
Vector in order to reveal possible enhancer elements located in more distant sequences 
upstream of the promoter. However due to time limitations these constructs have not been 
made. 
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2.3.3 Promoter analyses of hStamp2 5’-flanking sequences in 
prostate cancer cell lines 
 
Since it was previously found that hSTAMP2 expression is prostate enriched and androgen 
dependent 20 we used human PCa cell lines to verify the expression potential of the three 
forward inserts. Using the cationic lipid method, the respective reporter constructs were co-
transfected together with an AR expression vector (pSG5-AR) 31 into two AR-negative PCa 
cell lines, DU 145 and PC-3. After transfection, the cells were treated for 48 h with R1881, 
synthetic androgen. Vehicle (ethanol) was used for the control cells. The pSG5-AR amount 
used was optimized for both cell lines (data not shown). The -285-PB-LUC, described 
before as pPB(-285/+32)-LUC is a rat probasin promoter containing reporter plasmid 32 and 
served as a positive control, since its response is strongly androgen dependent. As shown in 
Figure 4a and 4b, the reporter expression of the positive control raised six to seven-fold 
upon androgen stimulation for both cell lines, indicating that both transfection and 
androgen treatment were successful. To examine the basal, androgen independent, activity 
of the putative promoter fragments, empty pSG5 was co-transfected with all three reporter 
constructs. In DU 145 cells co-transfected with empty pSG5 and the respective constructs 
(Figure 4A, pSG5) an increase in the reporter activity was observed that correlated with 
increasing insert length. Surprisingly, when the pSG5-AR construct were co-transfected 
with the promoter constructs a slight reduction (significant for the 2kb construct) of 
promoter activity upon androgen treatment was observed for all the constructs (Figure 4A, 
AR, black bar compared to gray bar). In addition AR expression appeared to have an 
androgen dependent inhibitory effect on the activity of the longest fragment. 
 
In contrast, the same reporter activity experiment carried out in PC-3 cells, showed a 
significant induction of promoter activity upon androgen treatment when pSG5-AR was 
transfected for all the constructs (Figure 4B, AR, black bar versus gray bar). Additionally, 
expression of the reporter increased with the length of the insert upon androgen treatment. 
However, the fold induction was to a much less extent than to that of the positive control. 
In addition, the basal activity was stronger for the 6kb compared to the other two constructs 
(Figure 4B, pSG5). For both experiments empty pGL2-Basic vector, co-transfected with 
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pSG5-AR, served as a negative control and showed low promoter activity (data not shown). 
Co-transfection of pSG5-AR with pGL2-Basic Vector containing the 6kb reverse insert 
showed low promoter activity, indicating directional specificity of the expression potential 
of the promoter (data not shown). The transfection efficiency, examined by β-gal assay 
described in section 2.2.2.4.3, was ~70% and ~40% for the DU 145 and the PC-3 cells 
respectively (data not shown). 
 
As described above, previous data from our laboratory have shown that STAMP2 is 
androgen regulated. This, together with the results of the transfection experiments in PC-3 
cells (Figure 4B) suggests that the hSTAMP2 promoter requires the presence of the AR for 
activation. For this reason, the different constructs were transfected into the AR positive 
cell line, LNCaP for promoter analyses. However, despite numerous attempts, using two 
different cell passages and two different transfection reagents, the transfection efficiency of 
this cell line was too poor (under 5%) to obtain any reliable reporter activity. This certainly 






























Figure 4.   Normalized transcriptional activity of the hSTAMP2 5’flanking region in AR 
negative prostate cancer cell lines 
2kb, 4kb, 6kb putative promoter luciferase reporter constructs were co-transfected with either 
empty vector (pSG5) or AR (pSG5-AR) expression plasmid into the (a) DU 145 or (b) PC-3 cells, 
as described in section 2.3.2.4.1. The cells were then treated for 48h with either vehicle (ethanol 
marked as EtOH) or R1881. -285PB-LUC, co-transfected with AR, served as a positive control for 
the androgen treatment. After harvesting, the cells were lysed and luminescence of each sample was 
measured to quantify reporter activity. Two experiments, each in triplicate, were carried out for 
each construct and the figure presents the data from the representative experiments. Values mark 
the mean of three measurements with the standard error (SE) bars. Values for the vehicle treated -
285PB-LUC- and vehicle treated pSG5+2kb -transfected cells were set to one. P values were 
assessed by student’s one-tailed t-test. Differences in reporter activity of vehicle treated versus 
androgen treated samples, that are statistically significant (P<0.05) or highly significant (P<0.01), 
are indicated by single and double star respectively. The significance has been calculated for the 
pSG5-AR-cotransfected 2kb, 4kb and 6kb and for the 6kb in DU 145 treated with androgen (pSG5 































































































































2.3.4 Effect of cycloheximide and actinomycin D on AR 
induction of hStamp2 expression and other androgen 
regulated genes 
 
Since the transfection results were conflicting in the two different cell lines described 
above, and did not indicate a direct effect of AR on the hSTAMP2 promoter activity in DU 
145 cells, experiments were undertaken to test whether the AR directly or indirectly effects 
STAMP2 expression. In order to answer this question, LNCaP cells were pretreated with 
CHX, an inhibitor of protein synthesis, followed by R1881 treatment. A transcription 
inhibitor, ActD was used in parallel with the CHX. To monitor the effect of these two 
compounds on androgen induced gene expression, total RNA was extracted from the 
treated and untreated cells, reverse-transcribed and the cDNA was analyzed by qRT-PCR. 
Normalized mRNA expression of five different genes was assessed (Table 3). PSA and 
NKX3.1 were used as positive controls of the CHX treatment, as results of similar 
experiments have previously been reported 34-37 .  
 
Figure 5 shows that the size of the different PCR products was as expected. None of the 
qRT-PCR controls were negative, indicating that the amplification is from cDNA only. 











Figure 5.   The size of the qRT-PCR products 
Specificity of the PCR product was verified by running 5μl of the total 10μl PCR reaction on a 1% 
agarose gel. One positive and one negative sample for each primer pair is represented in the picture. 
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Figures 6A and Figure 6B show that CHX has an inhibitory effect on androgen induced 
PSA and NKX3.1 expression with 81% and 29% reduction respectively, when compared to 
samples not treated with CHX. As shown in Figure 6C, hSTAMP2 androgen induction was 
strongly CHX sensitive (reduced by 94% compared to control). Additionally, the mRNA 
expression level after treatment with CHX was examined of two other proteins that our 
group is working with, Kallikrein4 (KLK4) and human translationally controlled tumor 
protein (hTCTP). For KLK4, a CHX-mediated reduction (28%) of androgen induced KLK4 
mRNA was observed (Figure 6D). hTCTP, of which expression was induced about 20% by 
androgen, revealed about four fold reduction in mRNA expression post CHX treatment 
(Figure 6E). Expression of the four out of five genes tested ( PSA, NKX3.1, hSTAMP2 and 
KLK4) (Figure 6A-D) was almost totally inhibited by ActD pretreatment, in contrast a 
much smaller but significant reduction in hTCTP transcripts were observed (Figure 6E). In 
general, ActD treatment resulted in loss of about 50% cells due to cell death (data not 
shown). This however, should not influence the results, since the expression of each gene 

























































































































































































































































Figure 6.   Normalized relative expression and effect of CHX and ActD on transcription of 
five androgen regulated genes 
LNCaP cells were pretreated with CHX, ActD or vehicle (EtOH) for 60 min followed by 24h 
treatment with either R1881 or vehicle (EtOH). Total RNA, extracted from harvested cells was 
reverse transcribed and cDNA subjected to qRT-PCR analysis .Expression of five different genes 
were investigated: (a) PSA, (b) NKX3.1, (c) hSTAMP2, (d) KLK4 (e) hTCTP and measurements 
were normalized to GAPDH (housekeeping gene) and mRNA concentrations were deduced. Two 
independent experiments, each in triplicate, were carried out for each gene investigated and the 
figures sum up data from both experiments. Values mark the mean of the six measurements with 
the standard error (SE) bars. The value for R1881 treated control cells was set to 100%. P values 
were assessed by student’s one-tailed t-test. Differences in mRNA concentration before and after 
treatment, that are statistically significant (P<0.05) or highly significant (P<0.01), are indicated by 
single and double star respectively. The values for some of the samples that was too low to appear 
in the figures are as follows: (a) Control, EtOH: 0.12, CHX, EtOH: 0.02, ActD, EtOH: 0.15, R1881: 
0.13, (b) ActD, EtOH: 0.01, R1881: 8.9×10-3, Control, EtOH: 0.02, CHC, EtOH: 0.05, ActD, 









































































2.4 Discussion  
 
 
In this study the putative hSTAMP2 promoter has been identified, characterized and 
analyzed. As mentioned above, both the identified human and mouse STAMP2 putative 
promoters are situated at the same localization on the 5’ gene region of the STAMP2 gene. 
Since homologues proteins between different species are likely to have promoters situated 
at similar sites in the gene locus, it is probable that the predicted human and mouse 
STAMP2 promoters are the true ones. Both promoters align with the first exon of the 
STAMP2 gene and share a number of TF binding sites located in same position in the 
promoter, as indicated in Table 4. Some of these and other TF binding sites, present only in 
the human promoter, were identified by more than one promoter program suggesting these 
putative TF sites are the true ones. The TF binding sites located only in the human 
promoter may reflect genuine evolutionary differences between two species. Some of the 
predicted TFs and their family members have been implicated in prostate and/or cancer 
development. E-26-like protein 1 (Elk-1) and epithelium-specific factor 2 (Ets-2) belong to 
the large family of Ets factors controlling cell proliferation, angiogenesis and metastasis 
during tumor progression 38. Ets factors were observed to have distinct functions in 
epithelial cell gene regulation, while ESE-2 was shown to transactivate the PSA promoter 
39. In addition, reporter gene assays have shown that Forkhead Box (FOX) A1 and GATA2 
are required for androgen-dependent PSA gene transcription 40,41. c-Rel, a member of the 
nuclear factor kappa B (NFκB) family have been reported to be required for chromatin 
remodeling across the IL-2 gene promoter in T cells 42. Furthermore, c-Rel was shown to 
activate antiapoptotic signaling, induce cell cycle progression and directly regulate 
transcription of the e2f3a promoter in B cells 43. Another study identifies c-Rel as a 
negative regulator of the AR and shows that c-Rel, together with AR, is a part of the 
nucleoprotein complex that regulates the PSA promoter, and its overexpression 
downregulates PSA transcription in LNCaP cells 44. Furthermore, simultaneous 
upregulation of NFκB and Ets have been observed in the abdominal aortic aneurysm 45. 
NFκB and CCAT/Enhancer-Binding Protein-β (C/EBP- β), of which site is also identified 
in hSTAMP2 putative promoter, have been reported to cooperate in the regulation of the 
IL-6 promoter in PC-3 and DU 145 cells 46. Signal transducer and activator of transcription 
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(STAT) 1 was observed to be overexpressed in DU 145 cells leading to drug resistance 47. 
STAT pathways were also shown to be activated by fibroblast growth factors (FGFs), of 
which expression is increased and which act as auto- and paracrine growth factors in the 
PCa cells 48. Moreover, STATs have been linked to IL-6 signaling, which has been 
implicated in PCa 49. Since retinoblastoma tumor suppressor protein (pRB), inhibitor of the 
E2 (adenoviral protein) factor (E2F), is expressed in PC-3 and mutated in DU 145, it has 
been observed that E2F3 gene overexpression can enhance proliferation of DU 145, but not 
PC-3 cells 50. Transcription of and transcription regulation mediated by both E2F1 and AR 
have been shown to be coregulated 51. All the findings concerning these TFs may indicate 
their importance in hSTAMP2 regulation. However, the computational analyses are 
hypothetical. Thus in order to asses relevance of each factor, the bioinformatics result 
should be empirically confirmed by laboratory methods, like EMSA, ChIP, DNase I 
footprinting assay, and cotransfection of TFs with the hSTAMP2 promoter constructs in 
reporter assays.  
 
The promoter analyses described above show that the 2kb fragment of the putative 
promoter of STAMP2 has promoter activity. In addition there was an increase in reporter 
activity that correlated with increasing insert length for both cell lines tested. These results 
suggest that the 2kb fragment contains the core promoter, while the upstream region 
encompasses the proximal promoter of STAMP2. An attempt has been made to identify 
elements of the core promoter. Three core promoter elements, TBP, E2F and C/EBP sites, 
have been identified by computational analysis (Figure 1) 52. It was previously reported that 
promoter analysis of the STAMP1 gene did not identify any significant TATA or CAAT 
box consensus sequences, indicating that this gene is transcribed from a TATA-less 
promoter 19. It has been proposed that many promoters do not contain consensus TATA 
boxes (reviewed in 53). However the putative core promoter elements identified in this 
study suggest that the hSTAMP2 core promoter contains a TATA box. hSTAMP2 cDNA 
was blasted against the nonredundant (nr) expressed sequence tags (ETS) database in order 
to localize the TSS (data not shown). However the results were unclear and could not be 
linked to the results obtained by computational methods. Further laboratory experiments, 
including primer extension analysis, will need to be undertaken to identify the TSS and the 
core promoter elements.  
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The gene reporter assays presented in this study (Figure 4) confirm the presence of a 
promoter in the 2kb 5’ UTR fragment for both cell lines tested. The possibility that the 
pSG5 constructs possesses promoter activity itself has been excluded, as no decrease in 
activity was observed for the reporter constructs transfected alone (data not shown) 
comparing to when they were cotransfected with pSG5 empty. The promoter acts in 
directional manner, as no activity was observed for the empty pGL2-basic vector and pGL2 
with the reverse 6kb putative hSTAMP2 fragment (data not shown). There is a tendency of 
increasing basal activity (when no AR is present) of all three constructs that is proportional 
to increasing length of the 5’flanking fragment in the DU 145 cells (Figure 4A, pSG5). 
This indicates that the promoter activity is androgen independent in this cell line. 
Interestingly, when AR is cotransfected into DU 145 cells and treated with androgen, an 
inhibitory effect is observed for the 2 kb fragment compared to when not treated with 
androgen (Figure 4A, black bars compared to gray bars). In addition AR expression 
appeared to have an androgen dependent inhibitory effect on the activity of the longest 
fragment (Figure 4A, 6kb, gray bar (pSG5) compared to gray bar (AR)). In conclusion, 
these results suggest that promoter activity in the DU 145 cell line is independent on the 
AR and that there are possible AR dependent inhibitory elements present in the 2kb 5’UTR 
as well as further upstream. 
 
In contrast, the reporter activity assays carried out in PC-3 cells indicate that the promoter 
is AR dependent (Figure 4B). Although relatively high androgen-independent promoter 
activity was observed, a significant increase in reporter activity was seen for all three 
construct tested when AR was present and treated with androgen compared to when not 
treated (black bars compared to gray bars, AR, Figure 4). In addition, the androgen 
dependent promoter activity was proportional to increasing length of the 5’flanking 
fragment in the PC-3 cells. Interestingly, the same androgen independent increase in 
promoter activity that was observed for the DU 145 cells is observed between the four and 
six kb upstream in PC-3 cells, indicating possible presence of androgen independent 
enhancer elements between the four and six kb upstream of hSTAMP2 gene. However, 
these results indicate that there are cell line dependent differences for the activity of the 
putative hSTAMP2 promoter in DU 145 and PC-3 cells. Cell lines, although derived from 
 61
the same tumor, may express proteins at different levels or modification status, and these 
differences can, at least to some extent, explain different response to therapeutic treatment 
54. In addition, cell lines derived from different tumors might have different signaling 
pathway network.  
 
Androgen depletion independent (ADI) PC can be divided into two types: type I, where the 
expression of the AR is lost, and type II, where AR acts as an oncogene 55. PC-3 and DU 
145 belong to the type I ADI PC cell lines. DU 145 is originally derived from a brain 
metastasis 56, while PC-3 is derived from a bone metastasis 57. Both of these cell lines have 
the p53-signalling pathway disrupted. The PC-3 cell line does not express p53 due to a stop 
codon introduced by mutation, while DU145 express a mutated version of this protein 54. In 
addition, the PC-3 cell line is phosphatase and tensin homolog deleted on chromosome ten 
(PTEN)-negative, resulting in a constitutively active PI3K/Akt pathway 58. In contrast, the 
DU 145 cell line expresses PTEN while the pRB and bax-genes are mutated 59. PC-3 cells 
do not express AR in spite of having no detectable changes in the gene itself compared cell 
lines expressing AR 60,61. In DU 145 cells, the AR promoter is methylated and thus not 
expressed 61. A number of studies have reported varying expression levels of signaling 
molecules between the DU 145 and PC-3 cell lines. One example is a study by Skjøth and 
Issinger where profiling analyses of factors involved in cell viability and apoptosis in PCa 
cell lines were carried out 54.  It was observed that DU 145 cells were more sensitive to 
cisplatin induced apoptosis, than the PC-3 and LNCaP cells 54. Western analysis showed a 
number of signaling molecules being differently expressed in PC-3 and DU 145 cells. The 
same study indicated that the Akt activity was almost three fold higher in PC-3 cells 
compared to that of DU 145 cells. This result coincides with the previously reported 
mutation of the inactive PTEN gene in PC-3 cells 58. In addition, Sharma and co workers 
have reported that PTEN negatively regulates the PI3K/Akt pathway, in which 
phosphorylation (inactivation) of glycogen synthase kinase-3 β (GSK3β) results in 
increased stability and nuclear level of β-catenin leading to elevated AR’s activity 62. β-
catenin has previously been shown to augment AR transcriptional activity 63. Thus inactive 
PTEN could also explain higher levels of phosphorylated GSK3β observed in PC-3 cells, 
as reported by Skjøth and Issinger 54. These results suggest that the β-catenin/AR-mediated 
transactivation level might be higher in the AR-transfected PC-3 than the AR-transfected 
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DU 145 cells. Numerous studies have measured the expression level of the various AR 
cofactors in PCa cell lines. For instance, Comuzzi and collaborators reported that the CBP 
coactivator protein expression level was significantly higher in PC-3 and LNCaP cells 
compared to that in DU 145 cells 64. Buchanan and coworkers have observed that another 
AR coactivator, glucocorticoid receptor interacting protein 1 (GRIP1), and an AR 
corepressor, SMRT, have more than two fold higher expression level in PC-3 cells than in 
DU 145 cells 65. Furthermore, differences of constitutive activation of MAPK in the PC-3 
cells versus DU 145 cells have been shown several times. To mention one example, 
Stangelberger and collaborates detected low levels of phosphorylated MAPK in PC-3 cells 
and PC-3 cell mice tumors, compared to DU 145 cells 66. Fujimoto and coworkers 
presented a novel putative AR coactivator, ARA55 that, by yeast-two-hybrid and co-
immunoprecipitation experiments, was found to bind AR 67. Northern analysis showed that 
ARA55 mRNA was detected only in PC-3 cells but not in DU 145 and LNCaP cells 67. In 
addition, another study reports that the steroid receptor activator (SRA), known to be a part 
of the steroid receptor coactivator-1 (SRC-1) complex 68, was detected at much higher 
levels in PC-3 cells, than in the DU145 and LNCaP cells 69. Linja and collaborators 
measured the expression of 16 different AR coregulators in PCa cell lines, xenografts and 
clinical specimen 70. It was reported that ARA24, amplified in breast cancer-1 (AIB1), and 
AIB3 expression was higher in the PC-3 cells compared to the DU 145 cells. Additionally, 
there was four-fold and over two-fold increase in expression of p300 and STAT1 
respectively. On contrary SRC1, protein inhibitor of activated STAT (PIAS) 1, PIASx, 
breast cancer 1, early onset (BRCA1), transcriptional intermediary factor 2 (TIF2), β-
catenin and NCoR1 were upregulated in the DU 145 cells 70. The four fold upregulation of 
the β-catenin in DU 145 cells, compared to that of PC-3 cells, does not correlate with the 
early mentioned hypothesis concerning the constitutively active PI3/Akt pathway in PC-3 
cells. From the studies described above, however, it is, possible that the NCoR corepressor 
upregulation in the DU 145 cells could account for the inhibitory effect of the AR upon 
androgen treatment observed in our luciferase assays. Moreover, the upregulation of the 
STAT1 in PC-3 cells is particularly interesting, since there is a STAT1 binding site 
identified in both human and mouse STAMP2 putative promoter (Table 4, Figure 1). In 
addition, Litvinov and coworkers claim that AR overexpression in the AR-negative cells 
itself is neither toxic nor advantageous and that the appropriate molecular mechanisms 
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must be present in the cell for the AR to act as either an oncogene or tumor suppressor. It 
was observed that lenti viral expression of AR in PC-3 cells resulted in upregulation of the 
cyclin dependent kinase (CDK) inhibitor, p21, and suppressed PC-3 cell growth (induced 
G1 arrest) both in culture and mouse xenografts. This was not observed for the DU 145 
cells tested, leading to conclusion that of these two cell lines, only PC-3 cells retained the 
necessary coregulators for the AR to function as a tumor suppressor gene. In contrast to 
these findings, Nightingale and coworkers observed suppressed DU 145 cell growth due to 
stable AR expression and DHT treatment 71. In summary, all these previous findings 
highlight significant differences between the DU 145 and PC-3 cells that may explain the 
different promoter activity of the hSTAMP2 promoter constructs with respect to androgen 
stimulation in our study. 
 
Furthermore, it was previously reported by our group that hSTAMP2 expression did not 
correlate with AR level in PCa samples, suggesting involvement of other factors in the 
hSTAMP2 gene regulation 20. In addition to the AR, AR cofactors are necessary for gene 
activation and their level and/or status may vary between these two cell lines. It has been 
reported before that NCoR and SMRT corepressors can be recruited by agonist-bound AR, 
leading to androgen dependent AR mediated gene repression 72. The outcome of the action 
of ligand bound AR thus depends on the relative levels of coactivators versus corepressors 
at the transcription site. It is therefore possible that the slight inhibitory effect of the 
androgen treatment in the DU 145 cells could be due to nuclear levels of cofactors that 
would favor hSTAMP2 gene repression. 
 
Alternatively, it is possible that both cell lines used in our experiments lack some of the 
cofactors for proper hSTAMP2 gene regulation. As illustrated in Figure 6C, androgen high 
induction of hSTAMP2 mRNA level in LNCaP cells was observed. Wild type AR and p53 
expressed in the LNCaP cells are just two examples of potential factors that could account 
for differences in hSTAMP2 gene regulation between this cell line and the two other AR-
negative PCa cell lines tested. LNCaP is an androgen-sensitive cell line obtained from 
lymph node metastasis 73,74. The strength of the LNCaP system is that it retains several 
salient features of human PCa: epithelial origin, expression of the AR, as well as AR-
regulated genes and androgen sensitivity for growth and survival in culture and xenografts 
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75. Over 90% of the PCa samples obtained from the patients are AR-positive 76. It is 
therefore of high importance to repeat the reporter gene studies in the STAMP2 positive 
cell line LNCaP. In conclusion, our results thus provide the basis for more detailed studies 
of hSTAMP2 gene regulation, in which particular factors, including AR cofactors, should 
be addressed.  
 
Table 5 lists the putative AREs identified in the putative hSTAMP2 promoter. As shown 
and discussed above, there was a significant increase in reporter activity by androgen for all 
three construct tested in PC-3 cells (Figure 4B). However, the fold difference of the 
androgen effect was to much less extent than the positive control. Even though the amount 
of the transfected AR was optimized (data not shown), the strongest induction obtained in 
the PC-3 cells was under two fold. As the constructs contain cis-regulatory elements taken 
out from the in vivo chromosomal context, it is possible that our 6kb fragment misses some 
regulatory sites, resulting in poor AR-dependent stimulation. In the recent study of Wang 
and coworkers  it has been reported that only 38% AREs were located within 500 bp of 
TSS in androgen regulated genes in LNCaP cells 77. Thus, functional AREs might be 
located further downstream or upstream of the gene, for instance in introns, as it has been 
shown for other androgen regulated genes 77-79. To examine this, further analyses of 
hSTAMP2 genomic DNA are required. Since computational analysis of such long DNA 
fragments may give a high number of hits one could use GREF_GATA model for AR 
binding sites. The GREF_GATA model is a model used in computational analysis of DNA 
sequences that localizes the AREs by combining the glucocorticoid responsive element 
matrix family (GREF) matches with the GATA matrix family matches, based on previously 
observed distance correlation of the same two families 80. Furthermore, additional 
mutational analysis of the putative AR binding sites would be useful to assess their 
importance for promoter activity.  
 
In addition to the direct effect of AR through ARE binding, AR may act indirectly by 
regulating transcription of an intermediary gene that in turn affects transcription of a gene 
or the half life of its mRNA and/or protein. Since nongenomic actions of the AR has been 
documented 17 and no major effect of androgen stimulation of the hSTAMP2 promoter 
activity was observed in the reporter studies described above, we hypothesized that AR 
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may indirectly regulate hSTAMP2. In order to investigate this, LNCaP cells were 
pretreated with CHX, an inhibitor of protein synthesis, followed by R1881 treatment. A 
transcription inhibitor, ActD, was used in parallel with the CHX. Detection of the mRNA 
level of PSA and NKX3.1 were used as positive controls. The CHX effect on the PSA 
androgen induction, resulted in a significant decrease of PSA mRNA, as reported before 34-
36 (Figure 6A). This suggests that, although AR directly binds to regulatory sites in PSA 
locus to activate transcription, proper androgen dependent expression of PSA requires de 
novo protein synthesis. On the other hand, as illustrated in  Figure 6B and reported by 
Prescott and collaborators, a smaller, but still significant, decrease of NKX3.1 mRNA was 
detected upon CHX treatment compared to the non-treated samples suggesting that AR 
transcriptional activation is more direct for NKX3.1 expression and not as dependent of de 
novo synthesized protein as expression of PSA 37. The results illustrated in Figure 6C 
confirm that expression of hSTAMP2 mRNA is AR dependent (black bars). When treated 
with androgen and CHX, there is a significant decrease in STAMP2 mRNA level compared 
to that treated with androgen only. This shows that hSTAMP2 mRNA expression is highly 
CHX sensitive and in similar fold to that of PSA, indicating that androgen induced 
transcription of STAMP2 involves action of labile proteins. This is in agreement with the 
suggestion that transcriptional regulation of hSTAMP2 regulation is a complex process, 
involving other factors than the AR alone. Androgen induction of the KLK4 gene was 
affected by CHX to a much lesser extent (Figure 6D), similarly to NKX3.1, suggesting that 
the androgen dependent transcriptional activation is more direct and less dependent on 
newly synthesized proteins that in case of the PSA and the hSTAMP2. The mRNA 
synthesis for the four gene described above was nearly blocked by the ActD treatment. 
 
Experiments from our laboratory have shown that TCTP expression is androgen regulated 
(unpublished results). qRT-PCR and Western blot analyses indicate that TCTP is more 
regulated on protein level compared to mRNA level in response to androgen, indicating 
post-transcriptional regulation of TCTP by AR. In the experiments described above (Figure 
6E) the effect of androgen stimulation on TCTP expression mRNA showed a 20% 
induction of TCTP mRNA upon androgen treatment.  This low androgen induction might 
be due to the androgen treatment time (24 h), as the experiments carried out recently 
indicate that TCTP upregulation is higher after 48 h treatment. The significant decrease in 
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the amount of mRNA under CHX treatment could indicate that de novo protein synthesis is 
required for TCTP transcription, regardless of AR presence. Surprisingly, a small but 
significant reduction in hTCTP transcripts was observed after ActD treatment. This weak 
ActD effect may suggest long half life of TCTP mRNA, exceeding the 24 hour CHX 
treatment. Thus, the four-fold decrease in TCTP mRNA upon CHX treatment could also 
indicate that labile proteins are required for mRNA stability, for instance involved in 
mRNA sequestration in a cell. TCTP, also called histamine-releasing factor (HRF), has 
been reported as a secreted protein that participates in inflammatory responses 81. Thus, 
storing of mRNA would allow for a quick synthesis of high number of proteins, with no 
need for gene transcription. Interestingly, a relatively long (~16 h) half life TCTP protein 
has been reported 82. Such long protein half life allows for rapid mobilization upon 
activation by inflammatory signal. Further experiments are required to examine the TCTP 
mRNA half life in LNCaP cells. As it has been reported that TCTP secretion is regulated 
by TSAP6 (STAMP3), a STAMP family member 82, it would be interesting to examine 
possible interaction of the hSTAMP2 with the TCTP. 
 
 
2.5 Conclusion and future perspectives 
 
Our results indicate that the putative hSTAMP2 promoter was identified, containing  a 
number of potential TF binding sites, of which some were also found in the mouse 
homologue. Some of these factors have been linked to prostate and cancer development. 
The reporter gene studies confirmed promoter activity in the 2kb fragment, in addition an 
increase in reporter activity correlated with increasing insert length. These results suggest 
that the 2kb fragment contains the core promoter, while the upstream region contains 
androgen dependent regulatory elements. No androgen effect was observed on the 
promoter activity in DU 145 cells. However, a significant increase in the promoter activity 
for all the constructs tested was observed upon androgen treatment in PC-3 cells. As 
discussed above, the differences in promoter activity of the STAMP2 promoter might 
reflect the heterogeneity of the two AR negative cell lines utilized. In addition, the 
androgen induced promoter activity observed in the PC-3 cell line was quite modest 
compared with the positive control. Taken together, these results may suggest indirect AR 
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involvement in the hSTAMP2 gene regulation that is cell line dependent. These data are 
also consistent with currently unidentified AREs in regions of the STAMP2 gene that are 
not analyzed in this study. These might be, located in further upstream and downstream 
enhancer regions, both canonical and noncanonical, with modified consensus sequence, 
AREs 77.  
 
The complexity of the androgen regulation of hSTAMP2 expression was supported in 
experiments where LNCaP cells were treated with CHX, suggesting the requirement of de 
novo protein synthesis for AR mediated hSTAMP2 gene induction. It will be important to 
analyze the promoter activity of STAMP2 in LNCaP cells as factors important for 
STAMP2 expression might be present. In addition, other important future studies are co-
transfections of the different TF that bind to the putative TF sites identified, as well as 
mutagenesis of the TF binding sites and AREs in the putative promoter, which might 
confirm the functional role of these factors. We could also utilize the ChIP-on-chip, a 
recently developed method that combines ChIP with tiled DNA oligonucleotide microarray 
analysis, and that has recently been used for mapping AR binding sites 77. In addition, 
EMSA, ChIP and DNase I footprinting analyses could be used to reveal binding of the TFs 
to their respective sites in the cis-regulatory elements. The enhancer and/or silencer 
elements could be further examined by inserting the two to four and four to six kb 5’UTR 
fragments to the pGL2-Promoter Vector. In addition the primer extension analysis would 
define the transcription start site of the hSTAMP2 gene and by narrowing the 5’UTR 2kb 
fragment in reporter gene assays one could localize more exact position of the core 
promoter. These and other experiments may help to reveal the function of STAMP2, a 
protein that one day may prove to be a useful diagnostic and therapeutic target in battling 
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